Iqvia Holdings Inc. (IQV)

$214.09

-2.16

(-1%)

Market is closed - opens 7 PM, 25 Jun 2024

Insights on Iqvia Holdings Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 3.90B → 3.74B (in $), with an average decrease of 4.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 469.0M → 288.0M (in $), with an average decrease of 38.6% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 11.6% return, outperforming this stock by 10.6%

  • Vs TMO

    In the last 3 years, Iqvia Holdings Inc. has experienced a drawdown of -10.2%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 1.1%

Performance

  • $213.46
    $218.29
    $214.09
    downward going graph

    0.29%

    Downside

    Day's Volatility :2.21%

    Upside

    1.92%

    downward going graph
  • $167.42
    $261.73
    $214.09
    downward going graph

    21.8%

    Downside

    52 Weeks Volatility :36.03%

    Upside

    18.2%

    downward going graph

Returns

PeriodIqvia Holdings Inc.Sector (Health Care)S&P500
3 Months
-13.11%
0.9%
4.4%
6 Months
-6.4%
8.7%
14.9%
1 Year
1.14%
11.2%
25.7%
3 Years
-10.23%
17.3%
28.1%

Highlights

Market Capitalization
39.4B
Book Value
$34.82
Earnings Per Share (EPS)
7.33
PE Ratio
29.5
PEG Ratio
1.33
Wall Street Target Price
271.36
Profit Margin
9.01%
Operating Margin TTM
13.94%
Return On Assets TTM
5.03%
Return On Equity TTM
22.11%
Revenue TTM
15.1B
Revenue Per Share TTM
82.42
Quarterly Revenue Growth YOY
2.3%
Gross Profit TTM
5.0B
EBITDA
2.8B
Diluted Eps TTM
7.33
Quarterly Earnings Growth YOY
0.02
EPS Estimate Current Year
11.08
EPS Estimate Next Year
12.45
EPS Estimate Current Quarter
2.48
EPS Estimate Next Quarter
2.66

Analyst Recommendation

Buy
    76%Buy
    23%Hold
    0
    0%Sell
Based on 26 Wall street analysts offering stock ratings for Iqvia Holdings Inc.(by analysts ranked 0 to 5 stars)
Based on 26 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
20
20
19
Hold
6
6
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 26.75%

Current $214.09
Target $271.36

Company Financials

FY18Y/Y Change
Revenue
10.4B
↑ 6.91%
Net Income
259.0M
↓ 80.21%
Net Profit Margin
2.49%
↓ 10.95%
FY19Y/Y Change
Revenue
11.1B
↑ 6.49%
Net Income
191.0M
↓ 26.25%
Net Profit Margin
1.72%
↓ 0.77%
FY20Y/Y Change
Revenue
11.4B
↑ 2.44%
Net Income
279.0M
↑ 46.07%
Net Profit Margin
2.46%
↑ 0.74%
FY21Y/Y Change
Revenue
13.9B
↑ 22.14%
Net Income
966.0M
↑ 246.24%
Net Profit Margin
6.96%
↑ 4.5%
FY22Y/Y Change
Revenue
14.4B
↑ 3.86%
Net Income
1.1B
↑ 12.94%
Net Profit Margin
7.57%
↑ 0.61%
FY23Y/Y Change
Revenue
15.0B
↑ 4.13%
Net Income
1.4B
↑ 24.47%
Net Profit Margin
9.05%
↑ 1.48%
Q4 FY22Q/Q Change
Revenue
3.7B
↑ 4.97%
Net Income
227.0M
↓ 19.79%
Net Profit Margin
6.07%
↓ 1.87%
Q1 FY23Q/Q Change
Revenue
3.7B
↓ 2.33%
Net Income
289.0M
↑ 27.31%
Net Profit Margin
7.91%
↑ 1.84%
Q2 FY23Q/Q Change
Revenue
3.7B
↑ 2.08%
Net Income
297.0M
↑ 2.77%
Net Profit Margin
7.97%
↑ 0.06%
Q3 FY23Q/Q Change
Revenue
3.7B
↑ 0.21%
Net Income
303.0M
↑ 2.02%
Net Profit Margin
8.11%
↑ 0.14%
Q4 FY23Q/Q Change
Revenue
3.9B
↑ 4.63%
Net Income
469.0M
↑ 54.79%
Net Profit Margin
12.0%
↑ 3.89%
Q1 FY24Q/Q Change
Revenue
3.7B
↓ 4.32%
Net Income
288.0M
↓ 38.59%
Net Profit Margin
7.7%
↓ 4.3%
FY18Y/Y Change
Total Assets
22.5B
↓ 0.85%
Total Liabilities
15.6B
↑ 8.42%
FY19Y/Y Change
Total Assets
23.3B
↑ 3.11%
Total Liabilities
17.0B
↑ 8.93%
FY20Y/Y Change
Total Assets
24.6B
↑ 5.65%
Total Liabilities
18.3B
↑ 7.63%
FY21Y/Y Change
Total Assets
24.7B
↑ 0.51%
Total Liabilities
18.6B
↑ 1.99%
FY22Y/Y Change
Total Assets
25.3B
↑ 2.62%
Total Liabilities
19.6B
↑ 4.96%
FY23Y/Y Change
Total Assets
26.7B
↑ 5.3%
Total Liabilities
20.6B
↑ 5.09%
Q4 FY22Q/Q Change
Total Assets
25.3B
↑ 4.6%
Total Liabilities
19.6B
↑ 3.69%
Q1 FY23Q/Q Change
Total Assets
25.7B
↑ 1.59%
Total Liabilities
19.8B
↑ 1.2%
Q2 FY23Q/Q Change
Total Assets
26.0B
↑ 1.15%
Total Liabilities
20.3B
↑ 2.43%
Q3 FY23Q/Q Change
Total Assets
26.0B
↓ 0.23%
Total Liabilities
20.2B
↓ 0.57%
Q4 FY23Q/Q Change
Total Assets
26.7B
↑ 2.71%
Total Liabilities
20.6B
↑ 1.97%
Q1 FY24Q/Q Change
Total Assets
26.6B
↓ 0.4%
Total Liabilities
20.2B
↓ 1.65%
FY18Y/Y Change
Operating Cash Flow
1.3B
↑ 29.28%
Investing Cash Flow
-810.0M
↓ 31.93%
Financing Cash Flow
-452.0M
↑ 527.78%
FY19Y/Y Change
Operating Cash Flow
1.4B
↑ 13.0%
Investing Cash Flow
-1.2B
↑ 46.91%
Financing Cash Flow
-276.0M
↓ 38.94%
FY20Y/Y Change
Operating Cash Flow
2.0B
↑ 38.25%
Investing Cash Flow
-796.0M
↓ 33.11%
Financing Cash Flow
-217.0M
↓ 21.38%
FY21Y/Y Change
Operating Cash Flow
2.9B
↑ 50.18%
Investing Cash Flow
-2.1B
↑ 164.2%
Financing Cash Flow
-1.2B
↑ 469.12%
FY22Y/Y Change
Operating Cash Flow
2.3B
↓ 23.18%
Investing Cash Flow
-2.0B
↓ 4.61%
Financing Cash Flow
-329.0M
↓ 73.36%
Q4 FY22Q/Q Change
Operating Cash Flow
560.0M
↓ 5.41%
Investing Cash Flow
-2.0B
↑ 179.78%
Financing Cash Flow
-193.0M
↓ 23.11%
Q1 FY23Q/Q Change
Operating Cash Flow
417.0M
↓ 25.54%
Investing Cash Flow
-222.0M
↓ 88.93%
Financing Cash Flow
87.0M
↓ 145.08%
Q2 FY23Q/Q Change
Operating Cash Flow
402.0M
↓ 3.6%
Investing Cash Flow
-596.0M
↑ 168.47%
Financing Cash Flow
95.0M
↑ 9.2%
Q3 FY23Q/Q Change
Operating Cash Flow
583.0M
↑ 45.02%
Investing Cash Flow
-1.4B
↑ 133.39%
Financing Cash Flow
-144.0M
↓ 251.58%

Technicals Summary

Sell

Neutral

Buy

Iqvia Holdings Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-5.81%
-6.4%
1.14%
-10.23%
37.36%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-4.02%
-10.84%
2.89%
-19.38%
80.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
-11.56%
-4.69%
12.57%
-9.15%
82.18%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-3.33%
6.59%
8.15%
13.98%
91.03%
Danaher Corp.
Danaher Corp.
-2.98%
10.18%
7.18%
-4.63%
79.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Iqvia Holdings Inc.
Iqvia Holdings Inc.
29.5
29.5
1.33
11.08
0.22
0.05
NA
34.82
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
48.06
48.06
4.75
11.05
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
31.97
31.97
2.7
5.23
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
35.72
35.72
2.81
21.72
0.14
0.05
0.0
119.24
Danaher Corp.
Danaher Corp.
46.58
46.58
3.13
7.61
0.08
0.04
0.0
72.16
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$39.4B
37.36%
29.5
9.01%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$41.0B
80.26%
48.06
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$39.4B
82.18%
31.97
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$212.7B
91.03%
35.72
14.2%
Danaher Corp.
Danaher Corp.
Buy
$187.7B
79.36%
46.58
18.55%

Institutional Holdings

  • Vanguard Group Inc

    11.56%
  • BlackRock Inc

    8.45%
  • Harris Associates L.P.

    5.57%
  • State Street Corporation

    4.37%
  • AllianceBernstein L.P.

    2.32%
  • Geode Capital Management, LLC

    2.28%

Company Information

quintiles and imshealth have merged together to form the new quintilesims. each wanting to bring something new to customers, we deliver integrated information and technology solutions to drive healthcare forward. quintilesims has approximately 50,000 employees conducting operations in more than 100 countries, dedicated to helping our clients improve their clinical, scientific and commercial results. as a global leader in protecting individual patient privacy, quintilesims uses healthcare data to deliver critical, real-world disease and treatment insights. to learn more, visit www.quintilesims.com

Organization
Iqvia Holdings Inc.
Employees
87000
CEO
Mr. Ari Bousbib
Industry
Health Services

FAQs